SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Savara Inc. securities between March 7, 2024, and May 23, 2025, due to alleged misleading statements regarding the company's Biologics License Application for MOLBREEVI [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Savara Inc. made false and misleading statements about the MOLBREEVI BLA, indicating that it lacked sufficient information regarding its chemistry, manufacturing, and controls [5]. - The lawsuit suggests that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [6].